Drug Trial Radar · NCT01166542
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Last checked: Nov 19, 2026Latest source record: Nov 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
167
Actual
Start
Jun 2010
Primary completion
Apr 2012
Study completion May 2014
Sponsor
- Lead sponsor
- Oncolytics BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus chemotherapy treatment alone, in patients with metastatic or recurrent Squamous Cell Carcinoma of the Head and Neck.
Conditions
- Carcinoma, Squamous Cell of the Head and Neck
Interventions
REOLYSINBiological
3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
CarboplatinDrug
5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
PaclitaxelDrug
175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: every 3 months until death.
Locations
77 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Arizona Oncology Associates
Tucson, Arizona
Providence Health and Services
Burbank, California
Wilshire Oncology Medical Group
Corona, California
BMS Physician Practice, A Medical Corporation DBA Medical Oncology Care Associates
Orange, California
Rocky Mountain Cancer Centers
Denver, Colorado
Pasco Hernando Oncology Associates, PA
New Port Richey, Florida
Emory University - Winship Cancer Institute
Altanta, Georgia
Alexian Brothers Hospital Network
Elk Grove Village, Illinois
Mary Bird Perkinds Cancer Center - Baton Rouge
Baton Rouge, Louisiana
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Montefiore Medical Center
The Bronx, New York
Case Comprehensive Cancer Center, University Hospitals Case Medical Center
Cleveland, Ohio
Mercy Cancer Center
Toledo, Ohio
Medical University of South Carolina
Charleston, South Carolina
Texas Oncology- Sammons Cancer Center
Dallas, Texas
Cancer Therapy and Research Center at UTHSCSA
San Antonio, Texas
Texas Oncology - Tyler
Tyler, Texas
Columbia Basin Hematology and Oncology
Kennewick, Washington
ZNA Middelheim
Antwerp, Belgium
University Hospital Antwerp
Edegem, Belgium
Universitair Ziekenhuis Brussel
Jette, Belgium
Tom Baker Cancer Centre
Calgary, Alberta, Canada
Juravinski Cancer Center
Hamilton, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Hopital Notre-Dame
Montreal, Quebec, Canada
Hopital Saint-André / Service d'Oncologie-Radiothérapie
Bordeaux, France
Centre Antoine Lacassagne / Oncologie Médicale
Nice, France
Institut Curie / Département d'Oncologie Médicale
Paris, France
UKE Hamburg
Hamburg, Germany
Attikon University Hospital
Athens, Greece
Fovarosi Onkormanyzat Uzsoki Utcai Kórház
Budapest, Hungary
Orszagos Onkologiai Intezet
Budapest, Hungary
Pecsi Tudomanyegyetem
Pécs, Hungary
Szegedi Tudományegyetem
Szegedi, Hungary
Markusovszky Korhaz
Szombathely, Hungary
Ufficio Sperimentazioni Cliniche c/o S.C. Oncologia Medica
Cuneo, Italy
Fondazione IRCCS Istituto Nazionale del Tumori
Milan, Italy
Showing 40 of 77 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.